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Abstract 
Maternal mental illness can have a devastating effect during the perinatal period, and has a 
profound impact on the care that the baby receives and on the relationships that the baby forms. 
This review summarises clinical evidence showing the effects of perinatal depression on offspring 
physical and behavioural development, and on the transmission of psychopathology between 
generations. We then evaluate a number of factors which influence this relationship, such as genetic 
factors, the use of psychotropic medications during pregnancy, the timing within the perinatal 
period, the sex of the fetus, and exposure to maltreatment in childhood. Finally, we examine recent 
findings regarding the molecular mechanisms underpinning these clinical observations, and identify 
relevant epigenetic and biomarker changes in the glucocorticoid, oxytocin, estrogen and immune 
systems, as key biological mediators of these clinical findings. By understanding these molecular 
mechanisms in more detail, we will be able to improve outcomes for both mothers and their 
offspring for generations.   
 3 
Introduction 
The perinatal period represents a time in which substantial brain development of the offspring 
occurs: during pregnancy, where the fetal genetic makeup interacts with maternal biology, and 
postnatally, influenced by the primary caregiver for nourishment, security and emotional 
regulation1,2. It is perhaps then no surprise that maternal mental disorders during this period, such 
as depression and postpartum psychosis, may have profound effects on the child’s social, emotional, 
behavioural and cognitive development.  
Maternal depression affects 10-15% of new mothers in both pregnancy and the postpartum period. 
It is associated with symptoms such as pervasive sadness, fatigue and rumination, which could 
impact mothers’ ability to bond with the baby in utero or postnatally, which may lead to a lack of 
mothers’ responsiveness to infant cues and to a disruption in the mother-child relationship.3,4 
Postpartum psychosis is far less common than postpartum depression, occurring in 1-2 of 1000 
childbearing women within the first 2-4 weeks after delivery5. It presents as early as 2-3 days after 
childbirth, with symptoms such as mood swings, confused thinking, grossly disorganised behaviour 
and paranoid, grandiose or bizarre delusions, and can severely impair the mother’s ability to look 
after her child, often resulting in temporary separation.  
There are consistent findings showing that the offspring of mothers suffering with perinatal mental 
health problems are more likely to have a psychopathology diagnosis in later life. This is likely to be 
influenced by the interplay of inherited genetic and epigenetic profiles, ‘fetal programming’, changes 
in neuroendocrine systems, and the experience of maternal care. This review starts by discussing 
clinical evidence of the effects of perinatal mental disorders on offspring outcomes, including the 
factors moderating this relationship, then explains some proposed biological mechanisms for this 
intergenerational transmission of psychopathology. Most of the evidence comes from studies on 
perinatal depression, although it is important to note that, in a majority of cases, perinatal 
depression is experienced together with clinically-significant anxiety3. It is therefore likely that the 
high arousal levels due to anxiety have a large contributory effect on parenting ability and perhaps 
on the biological mechanisms explained here, so this research has been included where appropriate. 
Much less research has been conducted on the consequences of postpartum psychosis on the 
offspring, and this evidence will be briefly considered in terms of the neuroendocrine and genetic 
alterations that accompany this disorder.  
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Clinical Evidence 
Developmental Outcomes in Childhood 
A mother’s attachment to her baby can be strongly influenced by her experience of depressive 
symptoms, resulting in difficulty bonding and non-optimal maternal behaviours. In turn, a baby’s 
early attachment relationship with the primary caregiver has a strong impact on its emotional 
regulation throughout development into adulthood6. Indeed, research suggests that offspring of 
depressed mothers typically show more behavioural difficulties7. The resulting attachment 
relationship can therefore be strained and affect multiple areas of the offspring’s emotional, 
behavioural, cognitive and social development.  
The main offspring abnormalities associated with perinatal psychopathology have been extensively 
reviewed before, for example recently by Stein and colleagues3. Hence, we concentrate here on 
reporting the most robust findings obtained in the largest available cohorts, which have usually 
investigated perinatal depression. These cohorts include: in the UK, the Avon Longitudinal Study of 
Parents and Children (ALSPAC)8–12, a birth cohort study with 14,000 women recruited in pregnancy; 
in Canada, the National Longitudinal Survey of Children and Youth (NLSCY)13,14, with over 35,000 
children and their mothers, and the Quebec Longitudinal Study of Child Development (QLSCD)15, 
with over 2000 children; and, in the Netherlands, the Generation-R cohort16–18, with nearly 10,000 
mothers recruited in Rotterdam, and the Tracking Adolescent’s Individual Lives Survey (TRAILS)19 
with a population of 2230.  
The most robust findings from these large cohorts are summarised in Table 1: they demonstrate an 
overall increased risk of internalising and externalising difficulties, as well as of low IQ, in the 
children of mothers suffering from perinatal depression. Antenatal depression, but not postnatal, is 
also associated with increased risk of depression in the offspring that manifests in adolescence and 
young adulthood, as further discussed below. However, it must also be noted that many other 
studies, although often with smaller sample sizes, do not find any such significant associations20,21, or 
even present contradictory findings20. Some of these other studies, for example, have found that 
perinatal depression alone has no significant impact, but, when comorbid with perinatal anxiety, it 
impairs development of the offspring.  
There are far fewer and smaller studies investigating the developmental impact on offspring of 
mothers experiencing psychotic symptoms. Interestingly, compared to women with depression, 
women with postpartum psychosis have no impairment in bonding, possibly because they do not 
share the same negative cognitions, and feelings of inadequacy and self-doubt, that influence the 
bonding experience of depressed mothers22. Still, mothers with psychosis appear similar to 
depressed mothers in interactive behaviour, with impaired responsiveness and less patience than 
mothers with no mental health problems, and one study found disturbances in both the bond to the 
infant and the interaction between mother and infant in this type of patient23. Interestingly, when 
mothers have delusions that the baby might be in danger, they are more likely to show affectionate 
behaviour and normal competence and care for baby’s basic needs; in contrast, when mothers have 
delusions that the baby is a devil or ill-fated, or is someone else’s baby, they are more likely to have 
significant abusive incidents towards the baby24. This points to an important role not just for the 
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diagnosis or the presence of symptoms, but also for the content of the symptoms that characterise 
the presentation.  
[TABLE 1 AROUND HERE] 
 
Psychopathology in Later Life 
Research has recently focused on ‘intergenerational transmission’ of maternal psychopathology to 
offspring, resulting in psychopathology later in life. Various studies have found that maternal 
antenatal depression is linked with offspring depression in adolescence and young adulthood10,25. 
The first study to describe this finding was the South London Child Development Study (SLCD), which 
includes 151 mother-child dyads and has found that adolescents exposed to antenatal depression 
have approximately 5-fold greater risk of depressive symptoms at age 16 than those not exposed25. 
The subsequent, much larger ALSPAC cohort has reported the increased risk of adolescent offspring 
mental disorder at 2-fold, compared with controls26, probably because it examines depressive 
symptoms in the community, as opposed to clinically-diagnosed depression in the SLCD study. A 
subsequent SLCD study paper has confirmed these findings when the offspring are young adults, at 
age 2527. Antenatal depression also increases the risk of offspring being diagnosed with emotional 
disorders by age 1628, and anxiety disorders by age 1829. Finally, a recent study has shown that 
maternal mood symptoms during and after pregnancy are risk factors for the development of 
disruptive mood dysregulation disorder by 11 years30.  
These effects of antenatal depression are likely to be mediated, at least in part, by biological changes 
in the in utero environment, as we extensively discuss below. However, postnatal factors are also 
very important: one proposed mechanism for this ‘transmission’ of depression from parent to 
offspring is via impaired parenting31, as shown by behaviours such as parental withdrawal and 
parental intrusion32, which are more common in mothers suffering with mental health problems. In 
contrast, a good parental environment, showing low levels of maternal over-involvement and high 
maternal warmth, produces higher resilience in offspring33.  
Interestingly, children born before 32 weeks’ gestation are 3-fold more likely to have depressive 
disorder than those who grow to term34, perhaps suggesting a further role for incomplete fetal 
development in the risk for psychopathology. As pre-term birth is associated with perinatal 
depression35,36, this could be another mechanism by which depression is ‘transmitted’ from mother 
to offspring.  
 
Potential Confounding Factors 
Despite the evidence suggesting a link between perinatal depression and an increase in 
developmental impairment and psychopathology in offspring, this should not be interpreted as 
indicating a deterministic relationship, as there are several factors which may confound or moderate 
this association. These factors operate from pregnancy through to the early life of the offspring, with 
a broad range of consequences, from buffering against the negative impact of perinatal 
psychopathology, to exacerbating its effects. Some of the best-studied of these include the role of 
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genetics, maternal childhood maltreatment and use of antidepressants during pregnancy. These 
factors will be discussed below. Other less studied factors, including the role of the father, feeding 
habits and the timing of mental health problems, are reviewed in Stein’s paper3.  
 
Genetics 
We cannot ignore the role of genetic inheritance in the intergenerational transmission of 
psychopathology, as a recent review on this topic clearly states37. The genetic heritability of major 
depressive disorder is well-established, with particularly robust evidence coming from twin studies, 
reporting around 40% heritability in women and 30% in men38. In addition to this, a major risk factor 
for adolescent psychopathology is family history, particularly parental depression39. More recently, 
the genetic influences on postpartum depression have been established, with the most common 
genes relating to major depressive disorder, such as those involved in the metabolism of key 
neurotransmitters, also showing an association with postpartum depression40 (some of the most 
robust findings are also discussed below, with reference to the relevant biological mechanisms). In 
addition, a genome-wide linkage study has identified the hemicentin 1 gene locus, to be associated 
with postpartum depressive symptoms41. Overall, one study recently reported that the heritability of 
perinatal depression as shown by a twin study design was 54%, whereas when using a sibling design, 
heritability was estimated at 44%. Interestingly, further analysis reported that 14% of the total 
variance in perinatal depression was unique for perinatal depression42.  
It is likely that the genetic predispositions for major depressive disorder and perinatal depression 
overlap substantially, and thus it is difficult to disentangle this genetic inheritance effect from the 
impact of environmental factors, either because of transmission of heritable genetic variants, or 
because of the role of genetic variants as moderators of the effects of the prenatal environment, 
through gene x environment interactions.  
In terms of transmission of heritable genetic risk from mothers to offspring, one approach that has 
attempted to disentangle this has been the use of a prenatal cross-fostering design including 
mothers either related or unrelated to their child as a result of in vitro fertilisation. In one such 
study, the reported association between prenatal stress and offspring outcomes show different 
genetic effects, i.e., prenatal maternal anxiety and depression predict offspring anxiety or antisocial 
behaviour in both related and unrelated mothers, while the link between prenatal stress and 
attention deficit hyperactivity disorder (ADHD) is explained solely by the genetic contribution43.  
A number of other study designs have confirmed that the intergenerational transmission of 
psychopathology is influenced, or moderated, by a genetic component. For example, the effects of 
low birth weight in increasing the risk of depression are stronger in children of depressed parents 
than in children with no such family history, indicating a genetic influence44. Indeed, several genetic 
variants have been found to moderate the relationship between birth weight and children’s social 
and emotional development, including classical ‘psychiatric genes’ such as the serotonin 
transporter45 and the dopaminergic receptor D446. As depression in pregnancy is associated with low 
birth weight35, it is likely that genetic variants also moderate the association between 
psychopathology in pregnancy and psychopathology in offspring. Indeed, recent reports found that a 
polygenic risk score for depression moderates the effects of antenatal depression on babies’ brain 
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development in the first days of life47, and a  polygenic score based on genes coexpressed with the 
serotonin transporter predicts the effects of prenatal adversities on children’s behavioural problems 
at 4-5 years48. Interestingly, this latter polygenic score seems to identify children that are not only 
more susceptible to prenatal ‘adverse’ environment, but also more likely to benefit from a 
‘supportive’ prenatal environment49.  
While GWAS-driven or biologically-informed polygenic scores have been used most frequently so far, 
it is also of note that we have recently published a cross-species approach, integrating data from a 
rat model of prenatal stress and human exposure to childhood maltreatment, which also identifies 
SNPs which show significant gene x environment interactions between exposure to stress and 
depressive symptoms50. 
 
Childhood Maltreatment 
There is a growing body of evidence suggesting that childhood maltreatment is a key moderating 
factor in the development of adolescent psychopathology in the offspring of depressed 
mothers27,51,52.  A study conducted by our group51 has shown that children exposed to antenatal 
maternal depression are twice as likely to report having experienced childhood sexual or physical 
abuse or harsh parenting by the age of 11 years, while such link is not present in the case of 
postnatal depression. Furthermore, offspring who have been exposed to both antenatal depression 
and childhood maltreatment are almost 12-fold more likely to have a diagnosis of depressive 
disorder or conduct disorder in adolescence, but exposure to one or other of these factors in 
isolation does not lead to an increased risk. We have recently replicated these findings in a 
subsequent follow-up of the offspring at age 2527. Interestingly, these studies also show that 
mothers suffering from antenatal depression are not more likely to be the sole perpetrators of 
maltreatment than healthy mothers; instead, the main perpetrators tend to be other close adults or 
even peers. Of note, a subsequent study conducted in the ALSPAC cohort has replicated the 
association between maternal antenatal depression and offspring exposure to childhood adversity53.  
 
Use of Antidepressants 
Studying the risks and benefits of antidepressant use in pregnancy is very important, as this time 
represents a key point at which clinicians could intervene to optimise outcomes for unwell mothers 
and their babies. However, the issue is highly complex, due to the difficulties in disentangling the 
potentially toxic effects of any antidepressants that reach the fetus via the amniotic fluid54, from the 
negative effects of untreated depression itself55. Then, after birth, the picture becomes more 
complex still, as the effect of any antidepressants (or metabolites) transmitted to the baby through 
lactation must be weighed against the impact on the parenting behaviours of the mother due to her 
depressive symptoms.  
The amount of research addressing the impact of antidepressants on a developing fetus or infant is 
substantial, especially for selective serotonin reuptake inhibitors (SSRIs), often the first-line 
treatment. SSRI use has increased during pregnancy in recent years, with up to 13% of pregnancies 
in both Europe and the US now involving exposure at some point56,57. The potential adverse effects 
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of antidepressants on the risk of congenital malformations have been extensively reviewed 
before58,59, and therefore will not be discussed here. In general, studies report that increased 
duration of antidepressant exposure is significantly associated with non-optimal obstetric outcomes, 
such as reduced gestational age, decreased birth weight, and increased risk of respiratory distress in 
the neonate60. However, untreated depression also reduces gestational age and birth weight35. The 
risk of reporting bias must also be considered, namely that a higher frequency of negative outcomes 
is reported by those taking antidepressants, as they are likely to be more vigilant. 
In terms of behaviour, neonates that have been exposed to SSRIs during late gestation show 
symptoms affecting the central nervous system as well as the motor, respiratory and gastrointestinal 
systems61. This neonatal ‘abstinence syndrome’ is present in up to 30% of exposed babies62, and 
manifests as crying, tremor, reflux, jitteriness and sneezing, as well as sleep disturbances63.  
There is also some suggestion that drugs used to treat maternal depression may affect the 
neurobehavioural development64,65 and psychomotor development66 of offspring, as well as slowing 
their reaching of major developmental milestones, such as sitting and walking unaided67. However, 
other studies show these effects to be transient68, and others do not find any association at all69. 
One study found that antidepressant dose and duration does not predict cognitive or behavioural 
outcomes, and that the IQs of offspring exposed to depression with or without antidepressant 
treatment in utero are similar, although lower than those of the offspring of nondepressed 
mothers70.  
While attention often focuses on the potentially toxic effects of psychotropic medications on a 
developing fetus, it is also important to consider the negative impact of depression in women not 
taking their medication. A study by Cohen et al.71 has shown that 70% of depressed women who 
discontinue medication relapse during pregnancy, mostly in the first and second trimesters. It is also 
more likely that those who suffer from depression during pregnancy will continue to suffer from 
depression after birth72, which may affect the care quality that the infant receives, further impairing 
development. There is also a significantly higher risk of self-medication in depressed pregnant 
women28, such as smoking or consuming alcohol and other legal and illegal drugs, and this also 
affects birth weight and other outcomes. Furthermore, despite concerns that psychotropic 
medications may be transmitted to the infant during breastfeeding, current evidence suggests that 
most medications show little or no risk to the infant73.   
Although this is a very difficult decision for every woman, on balance current evidence suggests that 
the consequences of untreated depression, especially for clinically-significant cases of depression, 
are more severe than those of antidepressants68,74–76, especially considering all the evidence 
reviewed in this paper that testifies to the profound and enduring negative consequences of 
antenatal depression on the offspring74. It is therefore vital that this risk of unmedicated depression 
is adequately evaluated before considering any detrimental effects of taking antidepressants.   
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Biological Mechanisms 
There are many potential mechanisms which explain how an adverse intra-uterine environment can 
predispose to disorders later in life, including inflammation, epigenetic regulation, the development 
of brain structures, and placental mechanisms regulating the passage of stress hormones, such as 
cortisol77, to the fetus. For postpartum psychosis, only few, very recent studies have started to 
evaluate the biological alterations in hormonal- and immune-mediated mechanisms, with biological 
samples usually acquired in the postpartum period. We will now review individual biological 
pathways, including specific genetic and epigenetic findings. For each pathway, we will first describe 
the available clinical evidence, and then we will present key preclinical evidence, where it adds 
further mechanistic insight.  
Before we start this section, however, it is important to highlight the complexity involved in the 
interpretation of epigenetic findings. Indeed, recent research focusing on the intergenerational 
transmission of psychopathology, and on the associated maternal parenting styles, has proposed 
epigenetics as a key mechanism78,79, with epigenetic changes occurring in the offspring in response 
to early life adversity80 and abnormal parenting behaviours81,82, and suggestions that these changes 
can be maintained over several generations by DNA methylation in the germline, although so far, 
pre-clinical evidence only supports this mechanism in the paternal germline83. As Szyf and Bick84 
suggest, DNA methylation is capable of “embedding early life experiences in the genome”. However, 
it must be noted that epigenetic transmission does not need to occur only via the classical 
inheritance mechanisms. For example, if mother and offspring are exposed to similar environmental 
circumstances, they may develop similar epigenetic signatures independently of inheritance. 
Epigenetics may also be influenced by the effects of health-related circumstances on the growing 
fetus and developing child. For example, recent research shows that maternal obesity85 can alter the 
methylation status of the infant, and maternal smoking can alter the methylation signature on the 
fetal side of the placenta86. Indeed, even the mode of delivery can alter the infant’s methylation 
status, as measured in leucocytes87. MicroRNAs are also considered a possible mediator of 
intergenerational effects on child outcomes, and indeed in the aforementioned paper from our 
group50 we have identified 68 miRNAs (out of a total of 1218 miRNAs) that are significantly 
modulated by prenatal stress in the offspring rat hippocampus. Contributing to this complexity is 
also the notion that non-genetic inheritance can occur in relation to psychiatric conditions, where 
traits or characteristics are transmitted via molecular substrates, such as hormones and cytokines, 
travelling from mother to fetus through cord blood88 .  Taken together, these lines of evidence 
demonstrate a need for caution when drawing ‘deterministic’ conclusions in the relationship 
between maternal behaviour and epigenetic changes in the offspring. 
 
Hypothalamic-Pituitary-Adrenal Axis 
The strongest body of evidence relating to perinatal psychiatry is that regarding the hypothalamic-
pituitary-adrenal (HPA) axis, which not only has its own effects via different regulation of the 
glucocorticoid receptor or circulating cortisol levels, but also interacts with other major biological 
systems. For example, the interaction of estrogen and progesterone with the HPA axis is thought to 
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be crucial in the pathogenesis of perinatal depression, and has also been proposed as one of the 
pathophysiological mechanisms underlying the rapid onset of postpartum psychosis89.  
 
The Maternal HPA axis and its Effects on the Fetus 
The accepted model postulates that  exposure of the fetus to high levels of cortisol may result in 
subsequent effects on HPA axis, behaviour, and cognitive function of the offspring90–97. For example, 
elevated levels of corticotrophin releasing hormone (CRH) and cortisol98–100  have been described in 
association with antenatal  symptoms of depression. Moreover, studies have found associations 
between antenatal HPA axis and offspring HPA axis101–103, or between antenatal HPA axis and infant 
behaviors or cognitive and motor development104–107. Interestingly, by adolescence, data shows that 
exposure to maternal anxiety during pregnancy may reduce the cortisol awakening response in 
offspring108, thus showing a complex and dynamic relationship between depression/anxiety-related 
HPA axis hyperactivity in pregnancy and changes in offspring HPA axis. The exact molecular 
mechanisms underlying these associations are however still unclear109. Here we present some of 
these mechanisms.  
 
Glucocorticoid Receptor and related genes 
Glucocorticoid hormones, the final product of the HPA axis, play a crucial role during fetal 
development, in processes such as tissue maturation and cellular differentiation110. The 
glucocorticoid receptor (GR) is a central mediator in fetal programming and in the development and 
regulation of the HPA axis, and has thus been the focus of much research in recent years111. There 
are many factors which affect the function and expression of the GR in the placenta, with one study 
showing that up to twelve different isoforms are present, whose expression can be dictated partly 
by fetal sex, as well as fetal size112. Recently, attention has turned to the effects of stress on the 
epigenetic profile of the GR.  
In humans, methylation of the GR gene in offspring is increased by parental psychopathology113 and 
early-life trauma114. However, it must be noted that, aside from a handful of studies looking at post-
mortem brains115–117,  human studies usually analyse the epigenome of peripheral tissues (most 
often, blood), which may not represent tissue-specific epigenetic changes occurring in the brain. 
Indeed, there is some debate about how reliable peripheral measurements are when compared to 
methylation changes in the brain. For example, one study in mice shows similar methylation changes 
of the GR-related gene, the FK506 binding protein 5 (FKBP5), in the blood and hippocampus 
following treatment with high dose of corticosterone118. Another paper demonstrates that a 
functional polymorphism in the FKBP5 gene increases the risk of developing stress-related 
psychiatric disorders by allele-specific, childhood trauma-dependent DNA demethylation, leading to 
a global effect on the function of immune cells and brain areas associated with stress regulation119. 
However, the blood-brain correlations may be smaller when using genome-wide analyses rather 
than individual, hypothesis-driven genes, or in other brain areas. For example, one study correlating 
epigenetic signatures in the blood and temporal lobe biopsy tissues shows that only 8% of 
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methylation markers are consistent in the blood and brain, although this is still more than expected 
by chance120. 
Antenatal stress also affects the epigenetic profiles of GR (and GR-related genes), but the effects in 
mother and infant are distinct. For example, maternal antenatal experience of war121 or of intimate 
partner violence122 increase the GR methylation status analysed in blood samples from the newborn, 
even into adolescence122, while mother’s epigenetic profile is unaffected. Moreover, pregnancy 
increases mRNA expression of the genes regulating the GR complex, FKPB5, BAG1, NCOA1 and PPID; 
however this increase is attenuated in women experiencing depression in pregnancy, indicating 
abnormal GR sensitivity123. While there are no data in pregnancy from women who later develop 
postpartum psychosis,  samples collected in the postpartum period from women with current 
symptoms of psychosis show that a dysregulation of the GR is also present in these women89. 
In addition to this clinical evidence, rodent models have shown that expression of the GR can be 
affected by the level of postpartum care, with the offspring of high licking-and-grooming mothers (a 
model of good maternal care) showing increased GR mRNA in the hippocampus and reduced HPA 
axis sensitivity to stress in adulthood124. Evidence in vitro points to serotonin, and in particular to the 
5-HT7 receptor, as playing a role in increasing GR expression in this experimental condition
125, with 
enhanced serotonergic signalling increasing the expression of the transcription factor, nerve growth 
factors inducible protein A (NGFI-A), which then interacts directly with the GR promoter to increase 
its expression126.  
Interestingly, a study by Weaver et al.81 in rats has shown that licking and grooming not only alters 
GR expression in the offspring, but also changes the epigenome at the GR gene promoter. Neonates 
of mothers that are ‘low licking-and-grooming’ (i.e., showing low maternal care) have differences in 
hippocampal GR methylation which persist into adulthood and are associated with 
hypermethylation of the exon 17, hypoacetylation of histone H3 and reduced NGFI-A binding. This is 
thought to increase the stress response, by decreasing the GR-mediated negative feedback on the 
HPA axis.  
Finally, our own in vitro work has shown that stress and glucocorticoids regulate neurogenesis in a 
human in vitro model using fetal hippocampal cells, as well as an animal model of prenatal stress127, 
via stimulation of the GR. SGK1, a Serine/Threonine kinase which is implicated in neuronal function 
and cellular stress responses, mediates this cortisol-induced reduction in neurogenesis by 
phosphorylation of the GR. Expression of mRNA encoding SGK1 has also been shown to be elevated 
in the peripheral blood of depressed patients128, suggesting that this molecular mechanism is 
relevant to the maintenance of psychopathology in adulthood.   
 
Cortisol and 11-Beta-Hydroxysteroid Dehydrogenase Type 2 
Epigenetic regulation of GR expression is not the only mechanism by which perinatal mental health 
can affect HPA axis function and regulation. As mentioned above, antenatal depression in humans is 
associated with high cortisol levels, a proportion of which is likely to be transported via the placenta 
to the fetus. To protect the fetus against some of these effects, the placenta forms a partial barrier 
which controls the proportion of maternal cortisol that reaches the fetus. Cortisol is converted by 
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the enzyme 11-beta-hydroxysteroid dehydrogenase type 2 (11β-HSD-2) into the less active, 
cortisone; however antenatal stress, depression, and exposure to antidepressants, reduce the 
expression of this enzyme129,130, potentially allowing the fetus to be exposed to the high cortisol 
levels in maternal circulation. In fact, it has been shown that low activity of placental 11β-HSD2 
correlates with lower fetal weight131 and with higher stress reactivity in the offspring129. Consistent 
with this, in rodents, the offspring of 11β-HSD2 knockout females are more prone to anxiety-related 
behaviours in later life132. 
On a molecular level, inhibition of this enzyme in the placenta has been shown to affect GR 
expression in varying ways across the brain, with mRNA levels increased in the amygdala, but 
reduced in the hypothalamic paraventricular nucleus133. Moreover, although the mechanism is 
unclear, sex differences are apparent in this protective mechanism, with male mouse fetuses 
showing superior protection to high levels of cortisol than females134. It is possible that this is caused 
by functional and expression changes in 11β-HSD2 due to differing methylation states of this 
enzyme, which are maintained in the offspring. In human preterm babies, lower levels of 
methylation of this enzyme are associated with a worse neurologic integrity and behavioural 
functioning135.    
 
Corticotrophin Releasing Hormone 
In the first few weeks after childbirth, it is characteristic for women to show hyporeactivity of the 
HPA axis136, as shown by blunting of the stress-related secretion of adrenocorticotrophic hormone 
(ACTH), a polypeptide tropic hormone. This hyporeactivity may be involved in explaining the 
sensitivity to mental health problems in the immediate weeks postpartum. In illustration of this, 
depressed mothers show more severe and long-lasting blunting of ACTH in response to 
corticotrophin releasing hormone (CRH) challenge at up to 12 weeks postpartum, in contrast to 
healthy women, for whom this blunting is less severe and has resolved by 12 weeks postpartum136. A 
blunted ACTH response to CRH is considered a hallmark of major depression, and it is interpreted as 
a consequence of the increased production of hypothalamic CRH in these patients137; therefore this 
evidence points toward an increased CRH drive also in perinatal depression (as mentioned above). In 
fact, one genetic association study found that a polymorphism in the CRH receptor 1 is associated 
with both pre- and post-natal depressive symptoms138, although another group was subsequently 
unable to replicate these findings in the ALSPAC cohort139.   
Indeed, CRH has been considered as a potential pregnancy biomarker, predicting the development 
of depression later in pregnancy or postnatally. One particular focus has been the elevated CRH 
levels produced by the placenta, particularly when stimulated by glucocorticoids140. CRH levels 
increase throughout pregnancy, via a positive feedback loop originating in the placenta64, with levels 
in the plasma peaking during the third trimester141, before rapidly dropping after childbirth142. A 
relatively small study of antenatally depressed and non-depressed women has shown that elevated 
maternal blood CRH levels in the blood from weeks 24 to 37 predict a higher likelihood of depressive 
symptoms in the antenatal period100; however this is conflicted by more recent research suggesting 
no such association142, and this association is also not found in the postpartum98. In our recent 
paper, women with clinically-significant depression in pregnancy show raised diurnal cortisol 
secretion, raised evening cortisol and blunted cortisol awakening response together with an 8-day 
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shorter length of gestation; most relevant to this review, these women also have neonates with 
suboptimal neurobehavioral function and increased cortisol response to stress at one year of age, 
and maternal cortisol correlates with infant stress response, suggesting a mechanistic link143. High 
levels of maternal CRH can also influence the neonatal behaviour of the offspring, such as impaired 
responses to novelty and heightened arousal144.  
 
 
Oxytocin 
Oxytocin, the hormone commonly associated with childbirth, maternal attachment and lactation145, 
is directly stimulated in offspring and mothers during attentive maternal behaviour. Indeed, mothers 
showing low maternal oxytocin levels during pregnancy are likely to show a lower frequency of 
positive bonding behaviour with their infants146. This may be due to the apparent reciprocal link 
between oxytocin levels and mood in the perinatal period: antenatal depression is associated with 
low levels of oxytocin after birth147, and low maternal oxytocin levels during pregnancy are 
significantly associated with  increased risk of developing postnatal depression148. Furthermore, 
there is some evidence to suggest that the genotype a woman carries at two loci for the oxytocin 
peptide, and one specific locus in the oxytocin receptor gene, can affect maternal interaction with 
her infant, and her experience of antenatal depression, respectively149.  
 
Administration of Intranasal Oxytocin 
Given this link, studies have attempted to use oxytocin therapeutically, by administering a dose 
intranasally and measuring its effects on maternal bonding behaviours, but results have not been 
conclusive. Some of these studies have shown that a dose of intranasal oxytocin induces more 
protective behaviour in postnatally depressed mothers, who usually have a higher risk of less 
attentive behaviour toward their baby150. Indeed, giving depressed mothers oxytocin increases their 
likelihood of rating the lowest pitch infant cries as urgent, when usually this type of cry is perceived 
as not urgent in healthy mothers; however, these oxytocin-treated mothers are also more likely to 
choose a harsh caregiving strategy151. It is therefore possible that (intranasal) oxytocin exacerbates a 
depressed mother’s sensitivity to stress and the negative cognitive processes associated with the 
interpretation of infant cues. In addition, there is some evidence to suggest that intranasal oxytocin 
may negatively impact maternal mood152, perhaps unexpectedly, given the negative correlations 
between oxytocin levels in the perinatal period and mood disorders discussed above. Indeed, a 
recent study has shown that women exposed to synthetic oxytocin in the peripartum period have 
over 30% increased risk of developing postpartum depression or anxiety153.  
The interpretation of these studies must be cautious, however, as recent evidence indicates that the 
majority of the intranasal dose of oxytocin does not reach the cerebrospinal fluid, but instead 
remains in the periphery, thus acting on other organs such as the gastrointestinal, cardiovascular 
and reproductive systems154. Recently it has been argued154 that many earlier trials reporting 
positive effects on maternal behaviour were conducted using inaccurate methods to process blood 
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samples prior to oxytocin analysis, and recommend that plasma samples should be extracted to 
avoid matrix interference, prior to oxytocin measurement.  
 
Regulation of Endogenous Oxytocin 
Clinical studies have shown a robust association between mother and offspring levels of oxytocin, in 
sample types such as plasma, saliva and urine155,156. One such study suggests that, mediated by level 
of maternal care experienced, both maternal and offspring levels of oxytocin predict children’s social 
development and interaction with peers157. Indeed, it is thought that well-adapted parenting is 
underpinned by oxytocin and the activation of reward-related brain mechanisms, while anxious 
parenting is associated with activation of stress-related regions of the brain158. This is further 
demonstrated by studies showing that securely attached mothers show more activation of oxytocin-
related regions of the brain, such as the hypothalamus and pituitary regions, on viewing their baby 
smiling or crying159. In addition to this, women with a history of childhood abuse have decreased 
oxytocin concentrations in the cerebrospinal fluid160.   
Recent clinical research also suggests that oxytocin and its response is regulated by epigenetic 
modifications of the oxytocin receptor gene (OXTR). There is suggestive evidence of a correlation 
between childhood neglect or abuse and higher methylation of two sites of OXTR, in exon 3161. 
Another study162 also showed a significant association between postpartum depression and 
methylation at cg12695586 on OXTR.  Furthermore, a higher number of stressful life events 
experienced by the mother during pregnancy, and elevated maternal cortisol levels, both reduce 
OXTR methylation in the cord blood163, but increase OXTR methylation in offspring at birth164. Finally, 
research in older people also indicates that methylation of the oxytocin receptor gene is dynamically 
regulated and influenced by environmental factors such as psychosocial stress165. Taken together, 
this evidence suggests that the epigenetic profile of the infant can be programmed in utero by 
stressful maternal experience. Nevertheless, this evidence is not unequivocal. The pathway leading 
from prenatal adverse environment to altered OXTR methylation in humans is complicated, based 
on the definition of prenatal adverse environment. For example, two studies, both assessing cord 
blood, use different dimensions of psychopathology and psychosocial environment, and find 
different associations:  one study found that increased number of life events in the two years up to 
middle gestation correlates with lower methylation (and hence, theoretically, higher expression)163, 
while another study (in children with severe conduct disorder) shows that prenatal maternal 
psychopathology, criminal involvement and substance use are associated with higher OXTR 
methylation, but only in children who have conduct disorder and lower internalizing problems, 
perhaps reflecting genetic confounding rather than a causal relationship between in utero 
environment and cord blood methylation164. 
Animal models have been used to study the effects of oxytocin in the brain in more detail. Oxytocin 
release, similarly to in humans, can be stimulated by attentive maternal behaviour, such as licking 
and grooming in rats166. Champagne and Meaney167 have shown that ‘high licking and grooming’ 
lactating female rats have higher expression of oxytocin receptor in multiple brain areas, including 
the hypothalamus (medial preoptic area, MPOA) and the central nucleus of the amygdala; moreover, 
maternal stress reduces oxytocin receptor expression in these brain areas, which in turn is 
associated with reduced maternal care and is transmitted to offspring who, in adulthood, also show 
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low oxytocin receptor levels and poor maternal care quality. However, other brain areas are also 
involved in the effects of oxytocin on maternal behaviour. For example blockade of the oxytocin 
receptor in the medial pre-frontal cortex of postpartum female rats impairs maternal care 
behaviours and enhanced maternal aggression168. In contrast, induction of the oxytocin receptor by 
estrogen in the ventromedial nucleus of the hypothalamus promotes female sexual behaviour, while 
induction in the central nucleus of the amygdala by dopamine gives rise to anxiolytic effects169. 
Taken together, this evidence points to multiple and complex effects of oxytocin beyond the simple 
regulation of maternal behaviour, depending on distinct signal transduction pathways and different 
regions of the brain, and tapping into a broad range of behavioural effects relevant to 
psychopathology.  
 
Estrogen 
Estrogen, a female sex hormone, is a potent regulator of a range of neural aspects such as mood and 
cognition142. Interestingly, a study in women with a history of postpartum depression reports that 
they show normal levels of circulating estrogen when euthymic, but abnormal sensitivity to 
childbirth-like estrogen withdrawal. Specifically, if these women are administered levels of estradiol 
and progesterone similar to those present during pregnancy, and then these hormones are 
withdrawn, mimicking the fall after childbirth, around 60% will develop mood symptoms, an effect 
which is absent in women with no history of postpartum depression170. This notion further 
supported by data showing that women with postpartum depression have increased sensitivity to 
estrogen signalling in the third trimester of pregnancy, as shown by enrichment of estrogen-
responsive mRNA transcripts’ expression in the blood171. Women at risk of postpartum depression 
are also more sensitive to reprogramming of estrogen-based DNA methylation of genes associated 
with synaptic plasticity in the hippocampus172. Finally, a genome-wide linkage study has identified 
the hemicentin 1 gene locus, which contains multiple estrogen binding sites, to be associated with 
postpartum depressive symptoms41, although this finding was no longer significant after adjusting 
for multiple comparisons. 
In addition to its independent actions, evidence emerging from preclinical models points to a 
pathway whereby the association between oxytocin, mood and maternal care behaviour discussed 
previously is also regulated by the presence of circulating estrogen and by epigenetic changes to the 
hypothalamic estrogen receptors78. This could contribute to this lifelong pattern of abnormal 
response of the oxytocin system to changes in circulating levels of estrogen, and thus to abnormal 
maternal care behaviour. Interestingly, however, reduced maternal care seems to be associated with 
decreased sensitivity to estrogen signalling, due to increased methylation and thus reduced 
expression of the ERα in the hypothalamus. This contrasts with the aforementioned evidence of an 
increased estrogen sensitivity in the blood of women at risk of post-partum depression. This 
inconsistency may be underpinned by different epigenetic and functional regulation in the blood and 
in the brain. 
A number of preclinical studies have confirmed the role of estrogen signalling in oxytocin regulation, 
including outcomes such as levels of maternal care. For example,  in mouse models of anxiety-like 
behaviour, treatment with oxytocin has anxiolytic effects that are absent in ovariectomised animals, 
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unless they receive estradiol supplementation, possibly because estrogen may act by increasing 
oxytocin binding density in the lateral septum of the brain173. Interestingly, these effects of estrogen 
on oxytocin regulation and activity seem to be specific for ER, as this is essential for estrogen’s 
induction of oxytocin receptor binding in the brain174. Indeed, studies conducted in the ‘licking and 
grooming’ model shows that the aforementioned differences in oxytocin receptor expression in the 
MPOA between high and low LG females are estrogen dependent175. A subsequent cross-fostering 
study confirmed an association between lower maternal care and decreased ERα expression in the 
MPOA, which is associated with higher levels of cytosine methylation across the ERα1b promoter82, 
eventually leading to the aforementioned decreased estrogen sensitivity.  
 
 
Neuroplasticity and Neurodevelopment 
The significance of early neurodevelopment as a risk factor for mental health disorders is becoming 
increasingly apparent77. Given that maternal mental illness during pregnancy has been shown to 
affect fetal neurodevelopment, it appears an important avenue of research when considering 
‘intergenerational transmission’ of psychiatric disorders.  
In the GUSTO (Growing up Towards Healthy Outcomes) study, a large and comprehensive birth 
cohort study in Singapore, prenatal maternal depression is associated with increased functional 
connectivity of the amygdala with the left temporal cortex and insula, as well as the medial 
orbitofrontal, bilateral anterior cingulate and ventromedial prefrontal cortices in the infant at 6 
months176; this is a pattern similar to that which is observed in adolescents and adults with major 
depressive disorder. However, a study from the same GUSTO cohort, but with a larger sample size, 
found that at age 4, prenatal maternal depressive symptoms were correlated with lower functional 
connectivity of the amygdala with other brain regions, although this was only observed in girls177.  
In another cohort, high levels of anxiety during pregnancy (particularly around week 19) is 
associated with a reduction in the density of grey matter in multiple regions of the brain of offspring 
aged 6-9, including the prefrontal cortex, premotor cortex, medial temporal lobe, postcentral gyrus 
and the cerebellum178. This altered grey matter could explain the increased risk of psychopathology 
in the offspring. Reduced hippocampal volume has been observed also in children who have 
experienced trauma in childhood, and has been reported in patients remitted with major 
depression179, so it likely contributes to resultant psychopathology in adulthood.  Further, significant 
cortical thinning in the right frontal lobes has been shown in children exposed to maternal 
depression in utero180. 
As well as anatomical changes, there also appears to be parallel changes in maternal and infant 
neurotransmitter regulation, with lower levels of dopamine and serotonin reported in depressed 
mothers during pregnancy being mirrored in offspring urine samples taken within 24h of birth181. 
Interestingly, recent preclinical evidence also suggests that the reduction in maternal hippocampal 
neurogenesis caused by prenatal stress can be reversed using SSRI treatment182.  
Of note, low levels of brain-derived neurotrophic factor (BDNF), which plays an important role in the 
development and maintenance of neural circuits, has been associated with vulnerability to the 
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development of various mental disorders in humans183, and we have shown a concomitant reduction 
in GR and BDNF mRNA levels in the same adult depressed patients184 . While direct clinical evidence 
in the perinatal period is lacking, rodent models show that BDNF expression in the offspring can be 
affected by both maternal antenatal stress and early life stress. Specifically, neonates of a prenatally 
stressed rat show a reduction in BDNF in both the olfactory bulbs and in the hippocampus185, while 
early maternal separation causes reduced levels of BDNF mRNA in the hippocampus of the offspring 
9 days post-birth186, and of BDNF protein in the medial prefrontal cortex (mPFC) in adulthood187. This 
potential long-lasting effect of antenatal stress on BDNF expression found in preclinical models 
supports a role for BDNF, and its subsequent effect on synaptic plasticity, as a risk factor for 
intergenerational transmission of psychopathology.  
 
 
 
Immune System  
Recently, it has become apparent that the process of biological embedding of perinatal or childhood 
stress into adult psychopathology is also underpinned by changes in inflammatory pathways188,189, as 
shown by studies in women suffering with postpartum depression190 as well as children exposed to 
maltreatment191. In addition, recent data from our group in the aforementioned paper143 have 
shown that women with antenatal depression have elevated levels of interleukin-6 (IL-6), tumour 
necrosis factor alpha (TNFα) , IL-10 and vascular endothelial growth factor during pregnancy; 
moreover, as for cortisol, maternal inflammatory biomarkers correlate with infant stress response, 
suggesting a mechanistic link.  
Depression is often manifested in conjunction with high levels of inflammatory biomarkers, 
especially in patients that are resistant to classic antidepressants192,193 and are exposed to 
maltreatment during childhood194. Indeed, many studies now show that the inhibition of pro-
inflammatory cytokines may improve low mood and, conversely, stimulation of the immune system 
may lower mood193,195,196. Furthermore, a number of studies have shown that adults who 
experienced childhood trauma show elevated levels of many immune biomarkers, such as c-
reactive-protein (CRP), TNF and interleukins188,197–199, an effect which can be seen in children as 
young as 12 years old191. There is also evidence that childhood exposure to medically-related 
inflammation, because of infections or medical disorders, is associated with a significantly increased 
risk of depression in adulthood200.   
There is some evidence that altered immune activation is present in pregnancy and in the 
postpartum period in association with depressive symptoms201,202. Indeed, one study has shown that 
regulatory T-cells are significantly increased in both the prenatal and postnatal period in mothers 
suffering depression190. Another study has shown that experience of abuse may be the key 
moderator of this relationship, as experience of abuse and depression in pregnant adolescents 
predicts higher IL-6 concentration during pregnancy, but none such association in absence of 
exposure to abuse203. However, other studies investigating cytokine levels have shown that 
depressive symptoms during pregnancy are negatively correlated with cytokines such as IL-1β, Il-7 
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and TNFa204,205. The results of these studies are partially confounded by the fact that, in general, they 
study variation of (self-related) depressive symptoms in large samples of pregnant women, rather 
than clinically-significant cases of antenatal depression. There is also evidence of an association 
between antenatal inflammation and behavioural outcomes in offspring206, suggesting that maternal 
inflammation may be relevant to some of the transgenerational outcomes observed in offspring. 
There is also evidence of an association between antenatal inflammation and behavioral outcomes 
in offspring206, suggesting that maternal inflammation may be relevant to some of the 
transgenerational outcomes observed in offspring. 
Higher levels of pro-inflammatory cytokines have also been reported in individuals with psychoses 
suggesting that inflammatory pathways may also underpin psychotic symptoms207,208, and in fact, a 
dysregulation of the immune system and glucocorticoid response has also been reported in 
postpartum psychosis89. Specifically, compared to postpartum women with no psychosis, those who 
develop postpartum psychosis have been found to have higher serum IL-1 levels and T-cell 
numbers, together with an upregulation of genes involved in the immune system89. In addition, 
women with postpartum psychosis show a decreased glucocorticoid receptor α/β gene expression in 
monocytes, which strongly correlates with the immune activation209. This points to the presence of 
alterations in both immune and neuroendocrine systems in postpartum psychosis that are similar to 
that observed in mood disorders and other psychoses. 
One possible molecular mechanism by which immune dysregulation is associated with 
psychopathology is through abnormal serotonin metabolism210. Indoleamine 2,3-dioxygenase (IDO) 
and tryptophan 2,3-dioxygenase (TDO) are the two major enzymes involved in the metabolism of 
tryptophan, the serotonin precursor. IDO is directly activated by pro-inflammatory signals, such as 
TNF and IFN, while TDO is activated by cortisol211,212. Of particular interest in pregnancy, TDO is 
also inhibited by estrogens and progesterone, a potential mechanism for the putative 
antidepressant effects of these hormones during pregnancy213.   
There is evidence that differences in the accumulation of neurotoxic kynurenine metabolites may 
precipitate the psychiatric symptoms in the perinatal period210,214. Indeed, a recent study202 has 
shown that both cortisol and the ratio between pro- and anti-inflammatory cytokines are elevated 
postpartum in mothers with depression (although TNF levels are significantly lower in depressed 
mothers), confirming the hypothesis that a combined increase in activators of both IDO and TDO 
could play an important role in serotonin availability. This mechanism may also participate to the 
association between antenatal depression and low fetal birth weight213, since tryptophan availability 
is vital for protein synthesis in fetal development.  
It is possible to speculate that epigenetic changes to the genes encoding immune molecules, as a 
result of perinatal or childhood adversity215, provokes long-term immune dysregulation, which then, 
in addition to the high cortisol levels associated with perinatal depression, may deplete serotonin 
availability in the offspring, thus maintaining the risk for depression in adulthood213. Indeed, we have 
recently shown that adult offspring of mothers who were depressed in pregnancy show, at age 25, 
increased inflammatory levels, as measured by blood CRP, even in the absence of depression; this 
confirms the notion that perinatal events, and antenatal depression in particular, induce long-term 
activation of the immune system in the offspring216. 
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Of note in this context is also the possibility of using omega-3 fatty acids, a potentially anti-
inflammatory treatment, as a safe antidepressant during pregnancy. In our trial using this approach 
in women with a diagnosis of major depressive disorder in pregnancy, we found that omega-3 
supplementation reduces depressive symptoms217. Subsequent studies that have investigated the 
prophylactic effects of omega-3 in women ‘at risk’ of depression in pregnancy or postpartum, 
however, have not found beneficial effects218,219, suggesting that the effects are most evident in 
more severe forms of antenatal depression. Our in vitro work has also recently shown that omega-3 
fatty acids, like some antidepressants, reduce activation of the IDO pathways220.  
A lot of research in animal models has used biological immune challenges, such as 
lipopolysaccharide, during pregnancy, to investigate the effects of a hyperactive maternal immune 
system on the developing fetus221–223. However, for this review we focus on psychological or stress 
challenges, as they are more relevant to prenatal psychopathology. Recent work224 has studied the 
effects of psychological stress in late gestation on postpartum neuroimmune function. After 
exposure to a forced swim test in late gestation, region-specific neuroimmune changes were 
observed in the mother’s brain postpartum, such as a reduction of IL-1 in the mPFC and an 
increased microglia density in the hippocampus. Increased expression of genes associated with the 
immune system can also be seen in the placenta following prenatal stress, particularly where the 
fetus is male, as shown by higher mRNA levels of IL-1225.  
Interestingly, changes in the expression of immune biomarkers can be seen also in the offspring 
following prenatal stress. For example, studies have reported increased levels of IL-1 mRNA in the 
hippocampus of both male226 and female227 offspring in adulthood (4 months). Interestingly, another 
study has shown increased inflammation in adult rats aged 6 months, with higher mRNA expression 
of interferon gamma (IFN) as a result of prenatal stress; however these alterations were 
undetectable in the rats when they were just 7 weeks old228. Recent evidence both in vitro229 and in 
vivo230 suggests that these long-lasting inflammatory alterations in adult rodents exposed to prenatal 
stress may be associated with malfunctions in fractalkine signalling, a chemokine important for the 
migration, differentiation and proliferation of neuronal and glial cells.  
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Concluding Remarks 
There is a wealth of research studying the effects of perinatal psychiatry on offspring outcomes, with 
at least three, parallel molecular pathways operating across the two generations: oxytocin, 
glucocorticoids, and inflammation (see figure 1). However, the methods of research are challenging, 
as experimental studies cannot capture the heterogeneity and complexity of the clinical conditions, 
and the clinical samples often present many contributing factors and outcomes that occur in parallel. 
For example, perinatal depression is often suffered in conjunction with perinatal anxiety or high 
current stress levels, and often in women with a previous history of mental illness and exposure to 
life adversity in childhood. In terms of outcome, and especially the increased risk of psychopathology 
in the offspring, it is important to note that the offspring of mothers suffering with depression are 
not only exposed to ‘the environment’ (for example, abnormal HPA axis function in utero or poor 
attachment and parenting behaviours postpartum), but are also likely to have a genetic 
predisposition to psychopathology, which may partly be related to the same molecular 
mechanisms231.  
Future research should investigate fetal programming in humans by combining in-depth clinical 
assessments with sophisticated molecular investigations, in cohorts of mothers and babies assessed 
prospectively. Ultimately, the ambition is that of elucidating the mechanisms by which the 
regulation of the maternal molecular systems discussed above can be ‘transmitted’ to the fetus and 
eventually culminate in psychopathology in the offspring during later life, and of using this 
understanding to predict, prevent or treat perinatal psychopathology, thus breaking the vicious 
intergenerational cycle.  
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Table 1: Summary of research findings from large cohorts relating to offspring outcome as a result of 
depression in the perinatal period.  
Offspring 
Outcome Factor 
Antenatal Depression Postnatal Depression 
 Study 
Details 
Findings Study 
Details 
Findings 
Internalising 
Behaviour 
Generation-
R, n=2698 
Associated with internalising 
behaviour at 3 years, as shown by 
emotional reactivity, 
anxiety/depression, somatic 
complaints and withdrawal16. [OR 
1.18 per 1 SD increase (95% CI 
1.08;1.29), p<0.001] 
TRAILS, 
n=2729 
Significantly 
associated with 
internalising 
difficulties in 
early 
adolescence19. 
[β=0.28 (95%CI 
0.14;0.41), 
p<0.001] 
Externalising 
Behaviour 
Generation-
R, n=2698 
Associated with child 
externalising difficulties, such as 
attention problems and 
aggressive behaviour16. [OR 1.19 
(95% CI 1.09;1.30), p<0.001] 
ALSPAC, 
n=3298 
Associated with 
offspring 
externalising 
behaviour such 
as inattention 
and 
hyperactivity11. 
[R2=0.09, 
p<0.05] 
Generation-
R, n=2280; 
ALSPAC, 
n=3442 
Higher risk of child attention 
problems17. [OR 1.23, (95% CI 
1.05;1.43); OR 1.33 (95% CI 
1.19;1.48)] 
QLSCD, 
n=2057 
Associated with 
high 
trajectories of 
inattention and 
hyperactivity-
impulsivity15. 
[OR 1.35 (95% 
CI 1.18;1.54)] 
ALSPAC, 
n=8598 
Increased risk 
of conduct 
problems12. 
[OR 1.74 (95% 
CI 1.33;2.52)] 
NLSCY, 
n=10033 
Association 
with physical 
aggression13. 
[OR 2.94, 
P<0.05] 
Emotional 
Development 
ALSPAC, 
n=2891 
Total emotional problems score 
negatively associated with 
exposure to antenatal 
depression, when controlling for 
psychological and maternal 
lifestyle variables8.  [β=0.22 (SE 
0.07), p<0.01] 
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Cognitive 
Development 
ALSPAC, 
n=5059 
Low full-scale IQ scores9. 
[SE=0.78, (95% CI 101.57;104.64)] 
ALSPAC, 
n=5059 
Low full-scale 
IQ scores9. 
[SE=1.17 (95% 
CI 
104.26;108.84)] 
Attachment Generation-
R, n=627 
Not associated with attachment 
insecurity18. [OR 0.96 (95% CI 
0.81;1.14)] 
Generation-
R, n=627 
Not associated 
with infant 
attachment 
insecurity18. 
[OR 0.91 (95% 
CI 0.75;1.10)] 
Adolescent 
Psychopathology 
ALSPAC, 
n=8937 
1 SD increase in maternal EPDS 
score positively associated with 
offspring depression aged 18 
years, when controlling for 
maternal lifestyle and depression 
history10. [OR 1.23 (95% CI 
1.03;1.44), p=0.025] 
NLSCY, 
n=937 
Infants exposed 
to depression 
at 2-3 years 
and 4-5 years 
postpartum 
had a 2-fold 
increased risk 
of emotional 
disorder at 12-
13 years14. 
 
